-DOCSTART- -X- O
Severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
is -X- _ O
frequently -X- _ O
complicated -X- _ O
with -X- _ O
acute -X- _ O
respiratory -X- _ O
failure. -X- _ O
In -X- _ O
this -X- _ O
article -X- _ O
, -X- _ O
we -X- _ O
aim -X- _ O
to -X- _ O
focus -X- _ O
on -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
the -X- _ O
subgroup -X- _ O
of -X- _ O
SARS -X- _ B-Patient
patients -X- _ I-Patient
who -X- _ I-Patient
are -X- _ I-Patient
critically -X- _ I-Patient
ill. -X- _ I-Patient
Most -X- _ O
SARS -X- _ B-Patient
patients -X- _ I-Patient
would -X- _ O
require -X- _ O
high -X- _ B-Intervention
flow -X- _ I-Intervention
oxygen -X- _ I-Intervention
supplementation -X- _ I-Intervention
, -X- _ I-Intervention
20–30 -X- _ I-Intervention
% -X- _ I-Intervention
required -X- _ I-Intervention
intensive -X- _ I-Intervention
care -X- _ I-Intervention
unit -X- _ I-Intervention
( -X- _ I-Intervention
ICU -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
high -X- _ I-Intervention
dependency -X- _ I-Intervention
care -X- _ I-Intervention
, -X- _ O
and -X- _ O
13–26 -X- _ O
% -X- _ O
developed -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
( -X- _ O
ARDS -X- _ O
) -X- _ O
. -X- _ O
In -X- _ O
some -X- _ O
of -X- _ O
these -X- _ O
patients -X- _ B-Patient
, -X- _ O
the -X- _ O
clinical -X- _ O
course -X- _ O
can -X- _ O
progress -X- _ O
relentlessly -X- _ O
to -X- _ O
septic -X- _ O
shock -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
multiple -X- _ O
organ -X- _ O
dysfunction -X- _ O
syndrome -X- _ O
( -X- _ O
MODS -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
management -X- _ O
of -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
SARS -X- _ I-Patient
patients -X- _ I-Patient
requires -X- _ O
timely -X- _ O
institution -X- _ O
of -X- _ O
pharmacotherapy -X- _ B-Intervention
where -X- _ O
applicable -X- _ B-Intervention
and -X- _ I-Intervention
supportive -X- _ I-Intervention
treatment -X- _ I-Intervention
( -X- _ I-Intervention
oxygen -X- _ I-Intervention
therapy -X- _ I-Intervention
, -X- _ I-Intervention
noninvasive -X- _ I-Intervention
and -X- _ I-Intervention
invasive -X- _ I-Intervention
ventilation -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Superimposed -X- _ O
bacterial -X- _ B-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
opportunistic -X- _ I-Outcome
infections -X- _ I-Outcome
are -X- _ I-Outcome
common -X- _ I-Outcome
, -X- _ O
especially -X- _ O
in -X- _ O
those -X- _ O
treated -X- _ O
with -X- _ O
mechanical -X- _ O
ventilation. -X- _ O
Subcutaneous -X- _ B-Outcome
emphysema -X- _ I-Outcome
, -X- _ I-Outcome
pneumothoraces -X- _ I-Outcome
and -X- _ I-Outcome
pneumomediastinum -X- _ I-Outcome
may -X- _ I-Outcome
arise -X- _ I-Outcome
spontaneously -X- _ O
or -X- _ O
as -X- _ O
a -X- _ O
result -X- _ O
of -X- _ O
positive -X- _ O
ventilatory -X- _ O
assistance. -X- _ O
Older -X- _ O
age -X- _ O
is -X- _ O
a -X- _ O
consistently -X- _ O
a -X- _ O
poor -X- _ O
prognostic -X- _ O
factor. -X- _ O
Appropriate -X- _ O
use -X- _ O
of -X- _ O
personal -X- _ O
protection -X- _ O
equipment -X- _ O
and -X- _ O
adherence -X- _ O
to -X- _ O
infection -X- _ O
control -X- _ O
measures -X- _ O
is -X- _ O
mandatory -X- _ O
for -X- _ O
effective -X- _ B-Patient
infection -X- _ I-Patient
control. -X- _ O
Much -X- _ O
of -X- _ O
the -X- _ O
knowledge -X- _ O
about -X- _ O
the -X- _ O
clinical -X- _ O
aspects -X- _ O
of -X- _ O
SARS -X- _ B-Patient
is -X- _ O
based -X- _ O
on -X- _ O
retrospective -X- _ O
observational -X- _ O
data -X- _ O
and -X- _ O
randomized-controlled -X- _ O
trials -X- _ O
are -X- _ O
required -X- _ O
for -X- _ O
confirmation. -X- _ O
Physicians -X- _ O
and -X- _ O
scientists -X- _ O
all -X- _ O
over -X- _ O
the -X- _ O
world -X- _ O
should -X- _ O
collaborate -X- _ O
to -X- _ O
study -X- _ O
this -X- _ O
condition -X- _ O
which -X- _ O
may -X- _ O
potentially -X- _ O
threaten -X- _ O
human -X- _ O
existence -X- _ O
. -X- _ O

